4.20Open4.20Pre Close0 Volume5 Open Interest4.00Strike Price0.00Turnover0.00%IV-4.98%PremiumDec 20, 2024Expiry Date4.63Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.96Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Anavex Life Sciences Stock Discussion
$Sunshine Biopharma (SBFM.US)$
$Rumble (RUM.US)$
Got a few superbouncy balls this evening.
making me dizzy 🤣
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences (Nasdaq: AVXL) announced it will present new long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial for blarcamesine in early Alzheimer's disease at the J.P. Morgan 2025 Healthcare Conference. The presentation will showcase data from up to 144 weeks of continuous treatm...
No comment yet